SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic...

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with complex origins.
• Current understanding posits DLBCL arises from follicular B cells involved in adaptive immunity.
• The BN2-DLBCL subtype presents unique genetic features requiring further investigation into its developmental trajectory.

Purpose of the Study:

• To investigate the developmental origin of the BN2-DLBCL subtype.
• To identify novel genetic drivers and cellular pathways involved in BN2-DLBCL pathogenesis.
• To explore sex-specific differences in DLBCL outcomes and potential therapeutic targets.

Main Methods:

• Analysis of co-occurring SPEN and NOTCH2 mutations in BN2-DLBCL.
• Utilizing animal models and human specimens to study clonal precursor expansion.
• Investigating X-chromosome-linked gene expression and toll-like receptor signaling in sex-biased outcomes.
• Preclinical evaluation of IRAK inhibition as a therapeutic strategy.

Main Results:

• A novel extra-follicular trajectory for BN2-DLBCL development was identified, driven by SPEN and NOTCH2 mutations.
• This pathway promotes the expansion of B-cell precursors with features of marginal zone, memory, and autoimmune states.
• Female patients and mice showed reduced survival, linked to enhanced X-chromosome-linked toll-like receptor signaling.
• IRAK inhibition demonstrated potential as a sex-specific therapeutic approach in preclinical models.

Conclusions:

• BN2-DLBCL originates from a distinct extra-follicular pathway.
• This pathway contributes to sex-biased survival disparities in DLBCL.
• Targeting IRAK offers a potential precision therapy for high-risk female patients.